68.61
Schlusskurs vom Vortag:
$66.98
Offen:
$66.64
24-Stunden-Volumen:
1.09M
Relative Volume:
0.76
Marktkapitalisierung:
$4.85B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-100.44M
KGV:
-30.91
EPS:
-2.22
Netto-Cashflow:
$-105.32M
1W Leistung:
+0.72%
1M Leistung:
+2.80%
6M Leistung:
+259.21%
1J Leistung:
+153.74%
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Firmenname
Structure Therapeutics Inc Adr
Sektor
Branche
Telefon
(650) 457-1978
Adresse
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Vergleichen Sie GPCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
GPCR
Structure Therapeutics Inc Adr
|
68.61 | 4.73B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Eingeleitet | Citigroup | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-21 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | Guggenheim | Buy |
| 2023-02-28 | Eingeleitet | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug - Finviz
H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 - Finviz
Why Structure Therapeutics Shares Are Surging Higher - TipRanks
Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement - BioSpace
Structure Therapeutics inks major GLP-1 licensing deal - MSN
Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight By Investing.com - Investing.com UK
Structure Therapeutics stock gets BMO Capital’s Outperform rating reaffirmed By Investing.com - Investing.com UK
Genentech makes $100M deal with South City neighbor to clear path for GLP-1 weight-loss drug - The Business Journals
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.4%What's Next? - MarketBeat
Voya Investment Management LLC Sells 14,230 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Analysts Are Bullish on These Healthcare Stocks: Palisade Bio (PALI), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Osaic Holdings Inc. Buys 31,972 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3%Here's Why - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 5.2%Here's Why - MarketBeat
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up - Eastern Progress
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Finviz
Structure Therapeutics stock price target raised to $90 from $60 at H.C. Wainwright - Investing.com
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – What’s Next? - Defense World
Avoiding Lag: Real-Time Signals in (GPCR) Movement - Stock Traders Daily
GPCRStructure Therapeutics Inc ADR Stock Price and Quote - Finviz
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpStill a Buy? - MarketBeat
Why Structure Therapeutics Shares Are Under Pressure Now - TipRanks
Pharmaceutical Stocks To Follow TodayDecember 8th - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novan (NOVN) and Pfizer (PFE) - The Globe and Mail
Structure Therapeutics begins phase 1 trial of oral obesity drug By Investing.com - Investing.com India
Structure Therapeutics begins phase 1 trial of oral obesity drug - Investing.com
New once-daily obesity pill enters first human tests using amylin biology - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 8.5%Should You Sell? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Price Target Raised to $120.00 - Defense World
Mid Cap Stocks To Watch TodayDecember 8th - MarketBeat
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Evommune, Inc. (EVMN) and Eli Lilly & Co (LLY) - The Globe and Mail
Bellevue Group AG Acquires 126,812 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Birchview Capital LP Buys Shares of 36,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Morgan Stanley - The Globe and Mail
Structure Therapeutics stock price target raised to $120 by Citizens - Investing.com South Africa
Structure Therapeutics (NASDAQ:GPCR) Raised to Hold at Wall Street Zen - MarketBeat
Structure Therapeutics Inc. (GPCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Federated Hermes Inc. Decreases Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics closes $747.5 million public offering - Investing.com
GPCR stock soars 102% on strong phase II obesity data for Aleniglipron - MSN
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by HighVista Strategies LLC - MarketBeat
Structure Therapeutics rises 101.6% - MSN
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies? - sharewise.com
Structure Therapeutics Announces $650 Million Public Offering - The Globe and Mail
Structure Therapeutics’ Leap: What’s Sparking the Surge? - StocksToTrade
Structure Therapeutics Shares Surge on Promising Drug Results - TipRanks
Structure Therapeutics Inc. (GPCR) Stock: Skyrockets After Positive Obesity Trial Result - Menafn
Structure Therapeutics prices upsized $650 million public offering By Investing.com - Investing.com South Africa
Finanzdaten der Structure Therapeutics Inc Adr-Aktie (GPCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):